Search Results

Chromocell Therapeutics Corporation today announced that its CEO Frank Knuettel, will be presenting at Alliance Global Partners Healthcare Company Showcase on Tuesday, May 21, 2024.

Benuvia Operations, LLC, a leader in pharmaceutical innovation, and Chromocell Therapeutics Corp., a pioneer in the development of non-opioid pain treatment therapeutics, are pleased to announce Chromocell’s first Development and License Agreement.

Chromocell Therapeutics Corporation announced the pricing of its initial public offering of 1,100,000 shares of common stock at a public offering price of $6.00 per share.

Chromocell Therapeutics Corporation (NYSE American: CHRO) (“Chromocell”, “our”, “us” or the “Company”), a clinical-stage biotech company focused on developing and commercializing new, non-opioid therapeutics to alleviate pain, today announced the closing of its initial public offering of 1,100,000 shares of its common stock at a public offering price of $6.00 per share.

Chromocell Therapeutics Corp. today announced that it has formally launched its eye pain treatment program with the hiring of Dr. Simon Chandler.

Chromocell Therapeutics Corp. today announced Frank Knuettel, CEO, will present and host one-on-one meetings with investors at the Sidoti March Virtual Investor Conference, taking place on March 13-14, 2024.